The latest price target for Praxis Precision Medicine (NASDAQ:PRAX) was reported by Oppenheimer on September 4, 2024. The analyst firm set a price target for $143.00 expecting PRAX to rise to within 12 months (a possible 138.81% upside). 27 analyst firms have reported ratings in the last year.

The latest analyst rating for Praxis Precision Medicine (NASDAQ:PRAX) was provided by Oppenheimer, and Praxis Precision Medicine reiterated their outperform rating.

There is no last upgrade for Praxis Precision Medicine

The last downgrade for Praxis Precision Medicines Inc happened on March 6, 2023 when William Blair changed their price target from N/A to N/A for Praxis Precision Medicines Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Praxis Precision Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Praxis Precision Medicine was filed on September 4, 2024 so you should expect the next rating to be made available sometime around September 4, 2025.

While ratings are subjective and will change, the latest Praxis Precision Medicine (PRAX) rating was a reiterated with a price target of $134.00 to $143.00. The current price Praxis Precision Medicine (PRAX) is trading at is $59.88, which is out of the analyst’s predicted range.